ACTIVITY OVERVIEW
Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).
AGENDA TOPICS
LEARNING OBJECTIVES
FACULTY
Professor of Hematology
Fondazione IRCCS Policlinico S. Matteo
University of Pavia
Pavia, Italy
Assistant Professor, Division of Hematology, Oncology, and Palliative Care
Department of Medicine
The University of Wisconsin School of Medicine and Public Health &
The University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, USA
St. James’s University Hospital
Haematological Malignancy Diagnostic Service
Leeds, United Kingdom
Associate Professor
University of California, San Diego
Moores Cancer Center
La Jolla, California, USA
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, USA
Technische Universität Müchen
Department of Medicine III
Munich, Germany
Assistant Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania
Philadelphia, PA, USA
Head Multidisciplinary Committee
Hematology Department
Gustave Roussy
Villejuif Cedex, France